Fundamentals-based quality & risk · not a recommendation
Epigral Ltd scores 66/100 (Quality) on the Orion Score — strong business quality (75), moderate growth (53), moderate balance-sheet safety (63) and fair valuation (60). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
18/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹736.16 | ₹80.95 | 17.2% | ₹18.76 |
| Q3 2026 | ₹597.12 | ₹39.11 | 10.1% | ₹9.07 |
| Q2 2026 | ₹587.36 | ₹51.22 | 15.3% | ₹11.87 |
| Q1 2026 | ₹606.54 | ₹160.69 | 20.1% | ₹37.25 |
| Q4 2025 | ₹627.63 | ₹86.89 | 22.2% | ₹20.14 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹2,495.48 | ₹331.97 | ₹555.7 | 16.0% |
| FY 2025 | ₹2,514.4 | ₹357.69 | ₹716.17 | 23.0% |
| FY 2024 | ₹1,893.83 | ₹195.87 | ₹476.64 | 18.9% |
| FY 2023 | ₹2,169.44 | ₹353.29 | ₹681.2 | 26.7% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| EPIGRAL ★ | ₹5,021 Cr | 15.13 | 14.31% | 16.09% | 0.26x | 17.24% |
| AETHER | ₹19,918 Cr | 90.08 | 11.68% | 9.38% | 0.19x | 21.06% |
| ATUL | ₹18,360 Cr | 27.11 | 10.56% | 11.53% | 0.03x | 12.07% |
| CHAMBLFERT | ₹18,180 Cr | 9.31 | 19.66% | 20.45% | 0.10x | 5.92% |
| ANURAS | ₹14,436 Cr | 82.66 | 8.65% | 5.76% | 0.41x | 18.15% |
| ACI | ₹6,512 Cr | 60.98 | 6.58% | 5.55% | 0.24x | 6.94% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹3,152.44 | ₹2,794.34 | ₹2,432.24 | ₹2,123.67 |
| Equity | ₹1,904.53 | ₹1,254.1 | ₹1,069.1 | ₹725.97 |
| Total Debt | ₹592.53 | ₹909.04 | ₹768.76 | ₹782.2 |
| Cash | ₹18.64 | ₹3.18 | ₹14.24 | ₹25.09 |
| Net Debt | ₹565.94 | ₹904.51 | ₹751.9 | ₹753.36 |
| Working Capital | ₹282.5 | ₹-277.65 | ₹-228.19 | ₹-85.35 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 69.99% ↑ | 3.07% ↓ | 2.51% ↓ | 24.43% ↓ |
| Q4 FY2026 | 68.86% ↑ | 3.35% ↑ | 2.75% ↓ | 25.04% ↑ |
| Q3 FY2026 | 68.83% | 2.36% ↓ | 5.13% ↑ | 23.67% ↑ |
| Q2 FY2026 | 68.83% | 2.71% ↓ | 4.93% ↑ | 23.52% ↑ |
| Q1 FY2026 | 68.83% ↓ | 3.06% ↑ | 4.78% ↑ | 23.3% ↓ |
| Q4 FY2025 | 68.95% ↑ | 3.01% | 4.66% ↑ | 23.34% ↓ |
| Q3 FY2025 | 68.94% ↓ | 3.01% ↑ | 4.31% ↑ | 23.71% ↓ |
| Q2 FY2025 | 71.58% | 2.1% | 1.17% | 25.12% |
| Ex-Date | Action | Details |
|---|---|---|
| 2026-06-01 | DIVIDEND | Dividend - Rs 5 Per Share |
Ask: "Is Epigral Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.